Kevin Joseph Fitzgerald Alnylam Pharmaceuticals, Inc. (ALNY) insider trading activity

Kevin Joseph Fitzgerald is CSO & EVP, Head of Research of ALNYLAM PHARMACEUTICALS, INC.. Currently has a direct ownership of 21,264 shares of ALNY, which is worth approximately $9.55 Million. The most recent transaction as insider was on Jan 13, 2026, when has been sold 2,290 shares (Common Stock) at a price of $370.8 per share, resulting in proceeds of $849,132. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 21.3K

15.72% 3M change

65.08% 12M change

Total Value Held $9.55 Million

Kevin Joseph Fitzgerald Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 13 2026	SELL Open market or private sale	$849,132 $370.8 p/Share	2,290 Reduced 9.72%	21,264 Common Stock
Jan 12 2026	SELL Open market or private sale	$550,848 $364.8 p/Share	1,510 Reduced 6.02%	23,554 Common Stock
Jan 11 2026	BUY Grant, award, or other acquisition	-	3,800 Added 13.17%	25,064 Common Stock
Nov 17 2025	SELL Open market or private sale	$5,538,857 $456.7 p/Share	12,128 Reduced 36.32%	21,264 Common Stock
Nov 17 2025	BUY Exercise of conversion of derivative security	$972,219 $119.13 p/Share	8,161 Added 19.64%	33,392 Common Stock
Oct 02 2025	SELL Open market or private sale	$1,104,113 $452.32 p/Share	2,441 Reduced 8.82%	25,231 Common Stock
Oct 01 2025	BUY Grant, award, or other acquisition	-	4,953 Added 15.18%	27,672 Common Stock

Aug 18 2025	SELL Open market or private sale	$631,424 $452.31 p/Share	1,396 Reduced 5.79%	22,719 Common Stock
Aug 15 2025	BUY Grant, award, or other acquisition	-	2,851 Added 10.57%	24,115 Common Stock
Jul 01 2025	BUY Grant, award, or other acquisition	-	7,763 Added 26.74%	21,264 Common Stock
Mar 04 2025	SELL Open market or private sale	$203,572 $241.2 p/Share	844 Reduced 5.88%	13,501 Common Stock
Mar 03 2025	SELL Open market or private sale	$468,042 $244.92 p/Share	1,911 Reduced 11.76%	14,345 Common Stock
Mar 03 2025	BUY Grant, award, or other acquisition	-	3,871 Added 19.23%	16,256 Common Stock
Feb 28 2025	SELL Open market or private sale	$119,387 $240.7 p/Share	496 Reduced 3.85%	12,385 Common Stock
Feb 18 2025	SELL Open market or private sale	$367,128 $254.95 p/Share	1,440 Reduced 10.06%	12,881 Common Stock
Feb 14 2025	SELL Open market or private sale	$171,140 $258.13 p/Share	663 Reduced 4.42%	14,321 Common Stock
Feb 13 2025	BUY Grant, award, or other acquisition	-	2,103 Added 12.31%	14,984 Common Stock
Nov 27 2024	SELL Open market or private sale	$386,715 $252.59 p/Share	1,531 Reduced 10.62%	12,881 Common Stock
Nov 26 2024	SELL Open market or private sale	$367,764 $250.35 p/Share	1,469 Reduced 9.25%	14,412 Common Stock
Nov 25 2024	BUY Grant, award, or other acquisition	-	3,000 Added 15.89%	15,881 Common Stock
Aug 12 2024	SELL Open market or private sale	$5,987,055 $271.83 p/Share	22,025 Reduced 63.1%	12,881 Common Stock
Aug 12 2024	BUY Exercise of conversion of derivative security	$1,893,436 $91.36 p/Share	20,725 Added 37.25%	34,906 Common Stock
Jun 25 2024	SELL Open market or private sale	$274,845 $229.42 p/Share	1,198 Reduced 7.79%	14,181 Common Stock
Jun 24 2024	BUY Grant, award, or other acquisition	-	2,498 Added 13.97%	15,379 Common Stock

Also insider at

OVID

Ovid Therapeutics Inc. Healthcare

KJF